Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan
We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18–89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2016-08, Vol.104 (2), p.256-265 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 2 |
| container_start_page | 256 |
| container_title | International journal of hematology |
| container_volume | 104 |
| creator | Kao, Hsiao-Wen Lin, Tung-Liang Shih, Lee-Yung Dunn, Po Kuo, Ming-Chung Hung, Yu-Shin Wu, Jin-Hou Tang, Tzung-Chih Chang, Hung Kuo, Tseng-tong Ou, Che-Wei Wang, Po-Nan |
| description | We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18–89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. The 2-year overall survival (OS) rate for all patients was 51.9 %. By multivariate analysis, bone marrow involvement (
P
1 (
P
= 0.007) were independent adverse factors for OS. A simplified prognostic index efficiently stratified patients into the following three groups: 2-year OS rates 79.8 % (0 factor), 28.3 % (1 factor), and 10.2 % (2 factors) by using bone marrow involvement and ECOG >1 (
P
1, IPI >1 and PIT >1 had adverse impact on OS. The usefulness of this simplified prognostic index needs further validation. |
| doi_str_mv | 10.1007/s12185-016-2010-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1811902306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1811902306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c457t-b5ec4007f87ed8f27014ace6c2e6194a7a7d13686255e6318dad9218ce95ab503</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1ERZfCD-CCLHHhQMqME3_kiFZ8SZV6Wc6W13G2rhJ7sR1V_fd1ugUhJPBlDn7mnXfmJeQNwiUCyI8ZGSreAIqGAUIjnpENKsGbVsruOdlAz3jDJcI5eZnzLQBK6OQLcs4k9Bw6tiFpO_ngrZno6ExZkssfaFyKjbOjJgz0mOIhxFy8paOxJaZM40iVpEdTvAsl0ztfbip68NHP8xLifjKP-I5aN010up-PN3E21Ae6M_7OhFfkbDRTdq-f6gX58eXzbvutubr--n376aqxHZel2XNnu7rlqKQb1FgtY2esE5Y5gX1npJEDtkIJxrkTLarBDH29h3U9N3sO7QV5f9KtO_xcXC569nn1ZIKLS9aoEHtgLYiKvvsLvY1LCtWdZqLnUtXX_Y9atbAFjrxSeKJsijknN-pj8rNJ9xpBr7HpU2y6xqbX2PQ6_-2T8rKf3fC741dOFWAnINevcHDpj9H_VH0AaPGhlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1811130515</pqid></control><display><type>article</type><title>Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Kao, Hsiao-Wen ; Lin, Tung-Liang ; Shih, Lee-Yung ; Dunn, Po ; Kuo, Ming-Chung ; Hung, Yu-Shin ; Wu, Jin-Hou ; Tang, Tzung-Chih ; Chang, Hung ; Kuo, Tseng-tong ; Ou, Che-Wei ; Wang, Po-Nan</creator><creatorcontrib>Kao, Hsiao-Wen ; Lin, Tung-Liang ; Shih, Lee-Yung ; Dunn, Po ; Kuo, Ming-Chung ; Hung, Yu-Shin ; Wu, Jin-Hou ; Tang, Tzung-Chih ; Chang, Hung ; Kuo, Tseng-tong ; Ou, Che-Wei ; Wang, Po-Nan</creatorcontrib><description>We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18–89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. The 2-year overall survival (OS) rate for all patients was 51.9 %. By multivariate analysis, bone marrow involvement (
P
< 0.001) and ECOG >1 (
P
= 0.007) were independent adverse factors for OS. A simplified prognostic index efficiently stratified patients into the following three groups: 2-year OS rates 79.8 % (0 factor), 28.3 % (1 factor), and 10.2 % (2 factors) by using bone marrow involvement and ECOG >1 (
P
< 0.001). In conclusion, AITL patients were older and had poorer prognosis in Taiwan. Bone marrow involvement, EOCG >1, IPI >1 and PIT >1 had adverse impact on OS. The usefulness of this simplified prognostic index needs further validation.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-016-2010-6</identifier><identifier>PMID: 27095042</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Bone marrow ; Bone Marrow Diseases - pathology ; Chemotherapy ; Hematology ; Humans ; Immunoblastic Lymphadenopathy - diagnosis ; Immunoblastic Lymphadenopathy - drug therapy ; Immunoblastic Lymphadenopathy - mortality ; Lymphocytes ; Lymphocytes T ; Lymphoma ; Lymphoma, T-Cell, Peripheral - diagnosis ; Lymphoma, T-Cell, Peripheral - drug therapy ; Lymphoma, T-Cell, Peripheral - mortality ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate analysis ; Oncology ; Original Article ; Patients ; Prognosis ; Remission ; Remission Induction ; Retrospective Studies ; Severity of Illness Index ; Survival ; Survival Analysis ; T-cell lymphoma ; Taiwan</subject><ispartof>International journal of hematology, 2016-08, Vol.104 (2), p.256-265</ispartof><rights>The Japanese Society of Hematology 2016</rights><rights>The Japanese Society of Hematology 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c457t-b5ec4007f87ed8f27014ace6c2e6194a7a7d13686255e6318dad9218ce95ab503</citedby><cites>FETCH-LOGICAL-c457t-b5ec4007f87ed8f27014ace6c2e6194a7a7d13686255e6318dad9218ce95ab503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-016-2010-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-016-2010-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27095042$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kao, Hsiao-Wen</creatorcontrib><creatorcontrib>Lin, Tung-Liang</creatorcontrib><creatorcontrib>Shih, Lee-Yung</creatorcontrib><creatorcontrib>Dunn, Po</creatorcontrib><creatorcontrib>Kuo, Ming-Chung</creatorcontrib><creatorcontrib>Hung, Yu-Shin</creatorcontrib><creatorcontrib>Wu, Jin-Hou</creatorcontrib><creatorcontrib>Tang, Tzung-Chih</creatorcontrib><creatorcontrib>Chang, Hung</creatorcontrib><creatorcontrib>Kuo, Tseng-tong</creatorcontrib><creatorcontrib>Ou, Che-Wei</creatorcontrib><creatorcontrib>Wang, Po-Nan</creatorcontrib><title>Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18–89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. The 2-year overall survival (OS) rate for all patients was 51.9 %. By multivariate analysis, bone marrow involvement (
P
< 0.001) and ECOG >1 (
P
= 0.007) were independent adverse factors for OS. A simplified prognostic index efficiently stratified patients into the following three groups: 2-year OS rates 79.8 % (0 factor), 28.3 % (1 factor), and 10.2 % (2 factors) by using bone marrow involvement and ECOG >1 (
P
< 0.001). In conclusion, AITL patients were older and had poorer prognosis in Taiwan. Bone marrow involvement, EOCG >1, IPI >1 and PIT >1 had adverse impact on OS. The usefulness of this simplified prognostic index needs further validation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Bone marrow</subject><subject>Bone Marrow Diseases - pathology</subject><subject>Chemotherapy</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunoblastic Lymphadenopathy - diagnosis</subject><subject>Immunoblastic Lymphadenopathy - drug therapy</subject><subject>Immunoblastic Lymphadenopathy - mortality</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Lymphoma, T-Cell, Peripheral - diagnosis</subject><subject>Lymphoma, T-Cell, Peripheral - drug therapy</subject><subject>Lymphoma, T-Cell, Peripheral - mortality</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>T-cell lymphoma</subject><subject>Taiwan</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1v1DAQhi1ERZfCD-CCLHHhQMqME3_kiFZ8SZV6Wc6W13G2rhJ7sR1V_fd1ugUhJPBlDn7mnXfmJeQNwiUCyI8ZGSreAIqGAUIjnpENKsGbVsruOdlAz3jDJcI5eZnzLQBK6OQLcs4k9Bw6tiFpO_ngrZno6ExZkssfaFyKjbOjJgz0mOIhxFy8paOxJaZM40iVpEdTvAsl0ztfbip68NHP8xLifjKP-I5aN010up-PN3E21Ae6M_7OhFfkbDRTdq-f6gX58eXzbvutubr--n376aqxHZel2XNnu7rlqKQb1FgtY2esE5Y5gX1npJEDtkIJxrkTLarBDH29h3U9N3sO7QV5f9KtO_xcXC569nn1ZIKLS9aoEHtgLYiKvvsLvY1LCtWdZqLnUtXX_Y9atbAFjrxSeKJsijknN-pj8rNJ9xpBr7HpU2y6xqbX2PQ6_-2T8rKf3fC741dOFWAnINevcHDpj9H_VH0AaPGhlA</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Kao, Hsiao-Wen</creator><creator>Lin, Tung-Liang</creator><creator>Shih, Lee-Yung</creator><creator>Dunn, Po</creator><creator>Kuo, Ming-Chung</creator><creator>Hung, Yu-Shin</creator><creator>Wu, Jin-Hou</creator><creator>Tang, Tzung-Chih</creator><creator>Chang, Hung</creator><creator>Kuo, Tseng-tong</creator><creator>Ou, Che-Wei</creator><creator>Wang, Po-Nan</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20160801</creationdate><title>Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan</title><author>Kao, Hsiao-Wen ; Lin, Tung-Liang ; Shih, Lee-Yung ; Dunn, Po ; Kuo, Ming-Chung ; Hung, Yu-Shin ; Wu, Jin-Hou ; Tang, Tzung-Chih ; Chang, Hung ; Kuo, Tseng-tong ; Ou, Che-Wei ; Wang, Po-Nan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c457t-b5ec4007f87ed8f27014ace6c2e6194a7a7d13686255e6318dad9218ce95ab503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Bone marrow</topic><topic>Bone Marrow Diseases - pathology</topic><topic>Chemotherapy</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunoblastic Lymphadenopathy - diagnosis</topic><topic>Immunoblastic Lymphadenopathy - drug therapy</topic><topic>Immunoblastic Lymphadenopathy - mortality</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Lymphoma, T-Cell, Peripheral - diagnosis</topic><topic>Lymphoma, T-Cell, Peripheral - drug therapy</topic><topic>Lymphoma, T-Cell, Peripheral - mortality</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>T-cell lymphoma</topic><topic>Taiwan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kao, Hsiao-Wen</creatorcontrib><creatorcontrib>Lin, Tung-Liang</creatorcontrib><creatorcontrib>Shih, Lee-Yung</creatorcontrib><creatorcontrib>Dunn, Po</creatorcontrib><creatorcontrib>Kuo, Ming-Chung</creatorcontrib><creatorcontrib>Hung, Yu-Shin</creatorcontrib><creatorcontrib>Wu, Jin-Hou</creatorcontrib><creatorcontrib>Tang, Tzung-Chih</creatorcontrib><creatorcontrib>Chang, Hung</creatorcontrib><creatorcontrib>Kuo, Tseng-tong</creatorcontrib><creatorcontrib>Ou, Che-Wei</creatorcontrib><creatorcontrib>Wang, Po-Nan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kao, Hsiao-Wen</au><au>Lin, Tung-Liang</au><au>Shih, Lee-Yung</au><au>Dunn, Po</au><au>Kuo, Ming-Chung</au><au>Hung, Yu-Shin</au><au>Wu, Jin-Hou</au><au>Tang, Tzung-Chih</au><au>Chang, Hung</au><au>Kuo, Tseng-tong</au><au>Ou, Che-Wei</au><au>Wang, Po-Nan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>104</volume><issue>2</issue><spage>256</spage><epage>265</epage><pages>256-265</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>We retrospectively analyzed 87 patients with angioimmunoblastic T cell lymphoma (AITL) in Taiwan. The median age was 68 (range 18–89) years. Of these patients, 74 % was at an advanced stage. The most common extra-nodal site involved was bone marrow (36 %). Of these patients, 77 % were International Prognostic Index (IPI) >1 and 79 % had a prognostic index for peripheral T-cell lymphoma (PIT) >1. Of 75 patients who received systemic chemotherapy, the complete remission rate was 60 %, the relapse rate was 47 %, and the 2-year progression-free survival rate was 37.4 %. The 2-year overall survival (OS) rate for all patients was 51.9 %. By multivariate analysis, bone marrow involvement (
P
< 0.001) and ECOG >1 (
P
= 0.007) were independent adverse factors for OS. A simplified prognostic index efficiently stratified patients into the following three groups: 2-year OS rates 79.8 % (0 factor), 28.3 % (1 factor), and 10.2 % (2 factors) by using bone marrow involvement and ECOG >1 (
P
< 0.001). In conclusion, AITL patients were older and had poorer prognosis in Taiwan. Bone marrow involvement, EOCG >1, IPI >1 and PIT >1 had adverse impact on OS. The usefulness of this simplified prognostic index needs further validation.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>27095042</pmid><doi>10.1007/s12185-016-2010-6</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2016-08, Vol.104 (2), p.256-265 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1811902306 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Bone marrow Bone Marrow Diseases - pathology Chemotherapy Hematology Humans Immunoblastic Lymphadenopathy - diagnosis Immunoblastic Lymphadenopathy - drug therapy Immunoblastic Lymphadenopathy - mortality Lymphocytes Lymphocytes T Lymphoma Lymphoma, T-Cell, Peripheral - diagnosis Lymphoma, T-Cell, Peripheral - drug therapy Lymphoma, T-Cell, Peripheral - mortality Medical prognosis Medicine Medicine & Public Health Middle Aged Multivariate analysis Oncology Original Article Patients Prognosis Remission Remission Induction Retrospective Studies Severity of Illness Index Survival Survival Analysis T-cell lymphoma Taiwan |
| title | Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A40%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20features,%20outcome%20and%20prognostic%20factors%20of%2087%20patients%20with%20angioimmunoblastic%20T%20cell%20lymphoma%20in%20Taiwan&rft.jtitle=International%20journal%20of%20hematology&rft.au=Kao,%20Hsiao-Wen&rft.date=2016-08-01&rft.volume=104&rft.issue=2&rft.spage=256&rft.epage=265&rft.pages=256-265&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-016-2010-6&rft_dat=%3Cproquest_cross%3E1811902306%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1811130515&rft_id=info:pmid/27095042&rfr_iscdi=true |